Zilia

We’re proud to share that the Zilia Ocular has been featured in a significant study conducted by Dr. Wendy Harrison's team at the University of Houston College of Optometry. This research highlights how our technology is reshaping our understanding of diabetic retinopathy (DR). 🔍 Key Insights from the Study: ➡️ Retinal oxygen saturation, measured in the macula, increases with duration of diabetes for both those with and without retinopathy, as well as with DR severity. ➡️ A clear inverse relationship was identified between vessel density and oxygen saturation, shedding light on the relationship between structural and functional changes in DR. ➡️ The study demonstrates how non-invasive ocular oximetry can provide critical insights into vascular and metabolic changes in diseases, opening the door to providing a novel biomarker for disease risk prediction and progression. 🙌 A heartfelt thank you to Dr. Harrison, Dr. Jennyffer Smith, and their colleagues—Dr. Kaitlyn A. Sapoznik, Dr. Kelly Bisignano and Dr. Julia Benoit—for their exceptional work and for choosing the Zilia Ocular technology to power their research. 📖 Read the full publication here: https://lnkd.in/eCtavSkb At Zilia, we are committed to advancing science and healthcare by unlocking the eye’s potential as a window into health. This study is another milestone in our mission to revolutionize how we detect and monitor ocular diseases. Stay tuned—more innovation is on the horizon! 🌍👁️ #Zilia #Innovation #OcularHealth #DiabeticRetinopathy #Oculomics

🚀 Milestone Achieved: 1,000 Patients Enrolled in Clinical Studies Zilia is proud to announce a significant achievement – over 1,000 patients are now enrolled in clinical studies using the Zilia Ocular platform! This milestone underscores the impact of our collaborations with world-class research institutions, including the University of Houston College of Optometry, the University of Montreal School of Optometry, and Kagawa University Faculty of Medicine. As CEO Patrick Sauvageau stated, "Reaching this milestone marks a pivotal moment in our mission to transform eye care. The enthusiasm with which leading ophthalmology and optometry research centers have integrated the Zilia Ocular in their work, and the exciting data that stems out of it, show the great potential and value of our technology." The Zilia Ocular platform addresses a critical unmet need in eye care by providing real-time measurements of oxygen saturation and other biomarkers. These insights are paving the way for groundbreaking advancements in understanding disease progression and treatment efficacy for conditions such as glaucoma and diabetic retinopathy. What’s next? We’re setting our sights on continuing to transform eye care – one patient (or 1,000!) at a time. Stay tuned, as this is just the beginning! #Zilia #ClinicalResearch #OcularOximetry #1KMilestone

We’re excited to announce that our CEO, Patrick Sauvageau, will represent Zilia at the #JMP25 Biotech Showcase in San Francisco, taking place January 13–15, 2025. This event is a fantastic opportunity to connect with fellow innovators, leaders, and investors who share our passion for driving progress in healthcare. 📩 Interested in meeting Patrick at the showcase? Send us a message—we’d love to connect and explore how we can innovate together! #Zilia #BiotechShowcase #OcularBiomarkers #HealthTech

Imagine a future where a routine eye exam reveals early signs of cardiovascular disease, neurodegenerative disorders, or even cancer. Thanks to the transformative field of #oculomics, that future is closer than ever. By leveraging biomarkers visible in the eye, oculomics empowers healthcare professionals to uncover critical health insights—non-invasively. With advancements in imaging technology and the integration of AI, the potential of this field is limitless. In our latest blog post, we delve into how groundbreaking innovations are turning what once seemed like science fiction into today’s reality. 👉 To the article: https://lnkd.in/dFNjtX5D 👉 Lire l'article: https://lnkd.in/dAr4hjBP

OIS XIV? We can’t miss it... and neither should you! We’re thrilled to announce that Zilia will be attending the Ophthalmology Innovation Summit (OIS) 2024, taking place November 22-23 at the Hard Rock Hotel in San Diego. This two-day summit brings together clinical, corporate, and capital leaders to explore groundbreaking advancements and drive the ophthalmic market forward. Representing Zilia is our CTO, Dominic Sauvageau, who will be on-site to share how our technology is revolutionizing eye care. 📅 Attending OIS? Let’s connect! #OIS2024 #OphthalmologyInnovation #MedTech #Zilia #DrivingInnovation

New Clinical Trial in Collaboration with the Medizinische Universität Wien! We're excited to share that Zilia is embarking on a groundbreaking clinical trial in collaboration with the Medical University of Vienna. This study aims to delve deeper into the intricate relationship between systemic hypoxia and retinal tissue oxygen saturation. 🎯 What's the Goal? By recruiting 20 healthy subjects, we'll utilize our innovative Zilia Ocular device to meticulously monitor changes in retinal tissue oxygen saturation under controlled hypoxic conditions. This research holds the potential to: ✔ Gain valuable insights into how systemic hypoxia impacts retinal health. ✔ Pave the way for the development of novel biomarkers that could revolutionize the early detection and management of various ocular diseases. We're grateful for the opportunity to collaborate with esteemed researchers at the Medical University of Vienna, particularly Prof. Gerhard Garhöfer, the principal investigator of this study. #clinicaltrial #retinalhealth #innovation #healthcare #Zilia #MedicalUniversityofVienna #eyehealth #biomarkers #hypoxia #research

👊 We're happy to share that Zilia’s latest research, co-authored by our very own experts, has been published today in Frontiers in Photonics! The study introduces a groundbreaking Principal Component Analysis (PCA)-based algorithm that significantly advances our ability to measure retinal blood oxygen saturation (StO₂) non-invasively using diffuse reflectance spectroscopy. The study demonstrates the accuracy and robustness of this algorithm, showcasing its potential to overcome existing challenges in real-time, quantitative retinal oximetry. With results validated on both simulated and experimental data, this technology represents a leap forward in the precision of metabolic assessments through the eye—one of the most sensitive indicators of overall health. Special thanks to Daniel Côté and his incredible team for their hard work and dedication in making this research a reality! 🔗 Read the full article here: https://lnkd.in/eSVNCSMn #Zilia #RetinalOximetry #OcularOximetry #PCA #DiffuseReflectanceSpectroscopy

Le 4 novembre dernier, notre CEO, Patrick Sauvageau, a eu l’honneur de participer à l’événement « La photonique et le quantique, vecteurs d'innovation pour le Québec », organisé par le COPL - Centre d'optique, photonique et lasers au Pavillon Alphonse-Desjardins de l’Université Laval. Cet événement marquait également le 35e anniversaire du COPL, une célébration de l’écosystème du centre. Le programme a survolé l’histoire du COPL, mettant en lumière la richesse de la synergie et des partenariats académiques et industriels, ainsi que l’innovation, le transfert technologique et l’entrepreneuriat scientifique qui le caractérisent depuis ses débuts. Patrick a pris part à une table ronde captivante intitulée « La R&D partenariale, ses mythes et réalités » aux côtés de Simon Thibault (Université Laval), John Zhang (Université Concordia), Paul Charette (Université de Sherbrooke), Michel Leblanc (EXFO), et Patrice Roulet Fontani (Immervision). Nous tenons à remercier chaleureusement les organisateurs et partenaires – COPL, Quantino, Université Laval, Optonique et Fonds de recherche du Québec – pour cet événement inspirant et riche en échanges. Crédit photo : Jean Rodier.

📢 New Research Highlights the Connection Between Ocular and Systemic Health A groundbreaking study from University of North Carolina at Chapel Hill has revealed a significant increase in comorbidities such as heart failure and dementia in patients suffering from both glaucoma and age-related macular degeneration. This important discovery reinforces the vital link between our eyes and the rest of the body’s health. Zilia is at the forefront of oculomics, leveraging the unique properties of the eye to support early detection and better management of systemic diseases. This new study further underscores the need for technologies like ours to measure objective metabolic biomarkers in the eye and help bridge the gap between vision care and overall health management. To the study ➡ https://lnkd.in/ebp6rxV2 #Oculomics #OcularHealth #Glaucoma #AMD #HeartHealth #Dementia #Zilia

It’s a wrap! 🎉 We had an amazing time at the 2024 American Academy of Ophthalmology meeting in Chicago, where we proudly showcased our advanced ocular oximetry technology. It was a fantastic opportunity to connect with industry professionals, share our vision for preventing vision loss, and demonstrate our innovative platform. To top it off, we even got to attend the Chicago Blackhawks home opener—talk about a win! 🏒 A special shoutout to our booth neighbors, Glaucoma Research Foundation and Olleyes.Inc—we couldn’t have asked for better company, right between groundbreaking research and cutting-edge innovation in eye care! Thank you to everyone who stopped by and made the event unforgettable. And if we missed you, you know how to reach us! 📩 #AAO2024 #Zilia #OcularOximetry #VisionCare #PreventBlindness #Innovation